Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period

Autor: Bujosa A, Moltó C, Hwang TJ, Tapia JC, Vokinger KN, Templeton AJ, Gich I, Barnadas A, Amir E, Tibau A

Publikováno v: Journal of the National Comprehensive Cancer Network
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

BACKGROUND: Most anticancer drugs are approved by regulatory agencies based on surrogate measures. This article explores the variables associated with overall survival (OS), quality of life (QoL), and substantial clinical benefit among anticancer dru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::25f3ffa6420e9ff767a340d99bc2f48c
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8023

Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011-2022).

Autor: Glaus CEG; Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland., Serra-Burriel M; Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, and Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland., Dusetzina SB; Professor of Health Policy and Ingram Professor of Cancer Research, Vanderbilt University School of Medicine, Department of Health Policy, and Vanderbilt-Ingram Cancer Center, Nashville, Tennessee., Vokinger KN; Professor of Law and Medicine, Academic Chair for Regulation in Law, Medicine, and Technology, Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.

Publikováno v: Annals of internal medicine [Ann Intern Med] 2024 Oct; Vol. 177 (10), pp. 1442-1444. Date of Electronic Publication: 2024 Sep 03.

Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses.

Autor: Serra-Burriel M; Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.; Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland., Martin-Bassols N; Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.; Department of Economics, University of Bologna, Bologna, Italy., Perényi G; Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.; Department of Mathematics, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland., Vokinger KN; Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.

Publikováno v: JAMA health forum [JAMA Health Forum] 2024 Aug 02; Vol. 5 (8), pp. e242530. Date of Electronic Publication: 2024 Aug 02.

Shortages of essential cancer medicines: who is responsible and what are the possible solutions?

Autor: Jenei K; London School of Economics, and Political Science, London WC2A 2AE, UK. Electronic address: k.jenei@lse.ac.uk., Lythgoe MP; Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK., Vokinger KN; Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Jan; Vol. 25 (1), pp. 23-26.

Do Managed Entry Agreements Contribute to Lower Pharmaceutical Spending?

Autor: Vokinger KN; Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.

Publikováno v: JAMA health forum [JAMA Health Forum] 2023 Dec 01; Vol. 4 (12), pp. e234610. Date of Electronic Publication: 2023 Dec 01.